Roth Capital Starts PlasmaTech Bio (PTBI) at Buy, $16 PT
Tweet Send to a Friend
Roth Capital initiates coverage on PlasmaTech Bio (NASDAQ: PTBI) with a Buy rating and a price target of $16.00.Analyst Elemer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
